Grassi et al. [115] retrospectively extracted clinical and 30-day CGM data before and after the initiation of low-dose once-weekly subcutaneous semaglutide (0.5 mg/week) in a cohort of 11 adult patients with long-standing T1D and excess body weight (overweight or obesity) who were on PLGM (predictive low-glucose management) with sensor-augmented insulin pump therapy and adhered to structured lifestyle modifications and education for weight management. This evidence concerns the gene INS and obesity disorder.